S&P 500   4,267.52
DOW   33,665.02
QQQ   348.82
Stock market today: Asian shares slip following technology selloff on Wall Street
“One-Stock Millionaire” IGNORES 99.9% of the Market (Ad)
Tesla: How and Why It Gets To $300
Don't Overlook Hidden Gem Kinsale As Rallies To New Highs
Stop Trading Like A Turtle (Ad)
AI-powered IoT Automation is Driving Samsara To New Highs
What is a Growth Stock Mutual Fund?
Stop Trading Like A Turtle (Ad)
Sprinklr Gets Targets Raised By Analysts, Here's Why
Time To Buy Uranium? Cameco Is The Top Pick
S&P 500   4,267.52
DOW   33,665.02
QQQ   348.82
Stock market today: Asian shares slip following technology selloff on Wall Street
“One-Stock Millionaire” IGNORES 99.9% of the Market (Ad)
Tesla: How and Why It Gets To $300
Don't Overlook Hidden Gem Kinsale As Rallies To New Highs
Stop Trading Like A Turtle (Ad)
AI-powered IoT Automation is Driving Samsara To New Highs
What is a Growth Stock Mutual Fund?
Stop Trading Like A Turtle (Ad)
Sprinklr Gets Targets Raised By Analysts, Here's Why
Time To Buy Uranium? Cameco Is The Top Pick
S&P 500   4,267.52
DOW   33,665.02
QQQ   348.82
Stock market today: Asian shares slip following technology selloff on Wall Street
“One-Stock Millionaire” IGNORES 99.9% of the Market (Ad)
Tesla: How and Why It Gets To $300
Don't Overlook Hidden Gem Kinsale As Rallies To New Highs
Stop Trading Like A Turtle (Ad)
AI-powered IoT Automation is Driving Samsara To New Highs
What is a Growth Stock Mutual Fund?
Stop Trading Like A Turtle (Ad)
Sprinklr Gets Targets Raised By Analysts, Here's Why
Time To Buy Uranium? Cameco Is The Top Pick
S&P 500   4,267.52
DOW   33,665.02
QQQ   348.82
Stock market today: Asian shares slip following technology selloff on Wall Street
“One-Stock Millionaire” IGNORES 99.9% of the Market (Ad)
Tesla: How and Why It Gets To $300
Don't Overlook Hidden Gem Kinsale As Rallies To New Highs
Stop Trading Like A Turtle (Ad)
AI-powered IoT Automation is Driving Samsara To New Highs
What is a Growth Stock Mutual Fund?
Stop Trading Like A Turtle (Ad)
Sprinklr Gets Targets Raised By Analysts, Here's Why
Time To Buy Uranium? Cameco Is The Top Pick
NASDAQ:CBAY

CymaBay Therapeutics (CBAY) Stock Forecast, Price & News

$9.42
-0.03 (-0.32%)
(As of 06/7/2023 ET)
Compare
Today's Range
$9.36
$9.63
50-Day Range
$8.50
$10.83
52-Week Range
$1.81
$11.22
Volume
716,659 shs
Average Volume
1.59 million shs
Market Capitalization
$918.54 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$14.57

CymaBay Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.14 Rating Score
Upside/​Downside
54.7% Upside
$14.57 Price Target
Short Interest
Healthy
10.39% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.88
Upright™ Environmental Score
News Sentiment
1.38mentions of CymaBay Therapeutics in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$1.39 M Sold Last Quarter
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.39 out of 5 stars

Medical Sector

179th out of 981 stocks

Pharmaceutical Preparations Industry

75th out of 468 stocks


CBAY stock logo

About CymaBay Therapeutics (NASDAQ:CBAY) Stock

CymaBay Therapeutics, Inc. engages in the provision and development of access to therapies for patients with liver and other chronic diseases with high unmet medical needs. Its products pipeline includes Seladelpar, MBX-2982, CB-0406, and CB-001. The company was founded on October 5, 1988 and is headquartered in Newark, CA.

Receive CBAY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CymaBay Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CBAY Stock News Headlines

The 10 Top-Rated Stocks by Wall Street Analysts in August 2021 (CBAY)
Analyst ratings reflect the sentiment of individuals who have significant knowledge of a company’s operations. For a company to be included on MarketBeat’s top-rated list they must have received at least five ratings within the last 12 months. Here are the 10 companies that have received the highest average rating by Wall Street analysts in August 2021.
Sell Every Stock, Except ONE (Ticker Revealed)
We saw one of the longest bull markets in history, with the S&P surging well over 800% But now the chickens have come home to roost. However, Jeff Clark couldn’t care less because he ignores almost every single stock in the market.
Sell Every Stock, Except ONE (Ticker Revealed)
We saw one of the longest bull markets in history, with the S&P surging well over 800% But now the chickens have come home to roost. However, Jeff Clark couldn’t care less because he ignores almost every single stock in the market.
Why CymaBay Therapeutics Stock Nose-Dived This Week
BTIG Reaffirms Their Buy Rating on CymaBay Therapeutics (CBAY)
Q1 2023 CymaBay Therapeutics Inc Earnings Call
CymaBay Therapeutics (CBAY) Receives a Buy from H.C. Wainwright
CymaBay Therapeutics: Slow But Steady Progress
CymaBay names new finance chief
See More Headlines

CBAY Price History

CBAY Company Calendar

Last Earnings
3/16/2023
Today
6/08/2023
Next Earnings (Estimated)
8/10/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CBAY
Employees
59
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$14.57
High Stock Price Forecast
$19.00
Low Stock Price Forecast
$12.00
Forecasted Upside/Downside
+54.7%
Consensus Rating
Buy
Rating Score (0-4)
3.14
Research Coverage
7 Analysts

Profitability

Net Income
$-106,000,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.43 per share

Miscellaneous

Free Float
92,052,000
Market Cap
$918.54 million
Optionable
Optionable
Beta
0.27

Key Executives

  • Sujal Shah
    President, Chief Executive Officer & Director
  • Daniel Menold
    Vice President-Finance
  • Harish Shantharam
    Chief Financial Officer
  • Charles A. McWherter
    President-Research & Development
  • Paul T. Quinlan
    Secretary & Chief Compliance Officer













CBAY Stock - Frequently Asked Questions

Should I buy or sell CymaBay Therapeutics stock right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CymaBay Therapeutics in the last twelve months. There are currently 6 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" CBAY shares.
View CBAY analyst ratings
or view top-rated stocks.

What is CymaBay Therapeutics' stock price forecast for 2023?

7 Wall Street research analysts have issued 1-year target prices for CymaBay Therapeutics' stock. Their CBAY share price forecasts range from $12.00 to $19.00. On average, they anticipate the company's stock price to reach $14.57 in the next twelve months. This suggests a possible upside of 54.7% from the stock's current price.
View analysts price targets for CBAY
or view top-rated stocks among Wall Street analysts.

How have CBAY shares performed in 2023?

CymaBay Therapeutics' stock was trading at $6.27 at the beginning of the year. Since then, CBAY stock has increased by 50.2% and is now trading at $9.42.
View the best growth stocks for 2023 here
.

Are investors shorting CymaBay Therapeutics?

CymaBay Therapeutics saw a decline in short interest in May. As of May 15th, there was short interest totaling 10,130,000 shares, a decline of 8.5% from the April 30th total of 11,070,000 shares. Based on an average trading volume of 1,700,000 shares, the short-interest ratio is presently 6.0 days.
View CymaBay Therapeutics' Short Interest
.

When is CymaBay Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023.
View our CBAY earnings forecast
.

How were CymaBay Therapeutics' earnings last quarter?

CymaBay Therapeutics, Inc. (NASDAQ:CBAY) issued its quarterly earnings results on Thursday, March, 16th. The biopharmaceutical company reported ($0.30) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.30). During the same period in the previous year, the business posted ($0.34) earnings per share.

What other stocks do shareholders of CymaBay Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CymaBay Therapeutics investors own include Sorrento Therapeutics (SRNE), NVIDIA (NVDA), Advanced Micro Devices (AMD), OPKO Health (OPK), Pfizer (PFE), Alibaba Group (BABA), Novavax (NVAX), Corbus Pharmaceuticals (CRBP), Energy Transfer (ET) and Viking Therapeutics (VKTX).

What is CymaBay Therapeutics' stock symbol?

CymaBay Therapeutics trades on the NASDAQ under the ticker symbol "CBAY."

Who are CymaBay Therapeutics' major shareholders?

CymaBay Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Perceptive Advisors LLC (4.01%), Franklin Resources Inc. (3.31%), BlackRock Inc. (2.72%), Bain Capital Life Sciences Investors LLC (2.57%), Commodore Capital LP (2.08%) and Balyasny Asset Management L.P. (2.01%). Insiders that own company stock include Charles Mcwherter, Dennis D Kim, Paul T Quinlan and Sujal Shah.
View institutional ownership trends
.

How do I buy shares of CymaBay Therapeutics?

Shares of CBAY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is CymaBay Therapeutics' stock price today?

One share of CBAY stock can currently be purchased for approximately $9.42.

How much money does CymaBay Therapeutics make?

CymaBay Therapeutics (NASDAQ:CBAY) has a market capitalization of $918.54 million. The biopharmaceutical company earns $-106,000,000.00 in net income (profit) each year or ($1.18) on an earnings per share basis.

How can I contact CymaBay Therapeutics?

CymaBay Therapeutics' mailing address is 7575 GATEWAY BOULEVARD SUITE 110, NEWARK CA, 94560. The official website for the company is www.cymabay.com. The biopharmaceutical company can be reached via phone at (510) 293-8800, via email at investors@cymabay.com, or via fax at 510-293-9090.

This page (NASDAQ:CBAY) was last updated on 6/8/2023 by MarketBeat.com Staff

My Account -